Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
Automated 96-well format high throughput colony formation assay for siRNA library screen
Journal article
Hatch SB. et al, (2022), STAR Protocols, 3, 101355 - 101355
-
An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status
Journal article
Lumley SF. et al, (2022), Clinical Infectious Diseases, 74, 1208 - 1219
-
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
Journal article
Wei J. et al, (2022), Nature Medicine
-
CHK1 inhibition exacerbates replication stress induced by IGF blockade
Journal article
Wu X. et al, (2022), Oncogene, 41, 476 - 488
-
A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation
Journal article
Nizami S. et al, (2021), Scientific Reports, 11